FORM 7  
  
MONTHLY PROGRESS REPORT

Name of Listed Issuer: Canntab Therapeutics Limited (the “Issuer”).

Trading Symbol: PILL

Number of Outstanding Listed Securities: 35,451,437

Date: November 30, 2020

**Report on Business**

1. Provide a general overview and discussion of the development of the Issuer’s business and operations over the previous month. Where the Issuer was inactive disclose this fact.

*On November 16, 2020, the Issuer has disclosed that Canntab and Exactus, Inc. mutually agreed to terminate the supply and distribution agreements previously announced on November 20, 2019, after determining that the regulatory requirements could not be completed on a timely basis.*

*During a time of pandemic and closed borders, both companies decided it would be best to mutually terminate the agreements in place. However, both companies have expressed an interest in working together in the future, and intend to make a decision in that regard once circumstances surrounding the COVID-19 pandemic have improved.*

1. Provide a general overview and discussion of the activities of management.

*None other than as described above.*

1. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

*Not applicable.*

1. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

*Not applicable.*

1. Describe any new business relationships entered into between the Issuer, the Issuer’s affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

*Not applicable.*

1. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer’s affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

*Not applicable.*

1. Describe any acquisitions by the Issuer or dispositions of the Issuer’s assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

*Not applicable.*

1. Describe the acquisition of new customers or loss of customers.

*Not applicable.*

1. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

*Not applicable.*

1. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

*Not applicable.*

1. Report on any labour disputes and resolutions of those disputes if applicable.

*Not applicable.*

1. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

*Not applicable.*

1. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

*Not applicable.*

1. Provide details of any securities issued and options or warrants granted.

*Not applicable.*

|  |  |  |  |
| --- | --- | --- | --- |
| **Security** | **Number Issued** | **Details of Issuance** | **Use of Proceeds(1)** |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |

*(1) State aggregate proceeds and intended allocation of proceeds.*

1. Provide details of any loans to or by Related Persons.

*Not applicable.*

1. Provide details of any changes in directors, officers or committee members.

*Not applicable.*

1. Discuss any trends which are likely to impact the Issuer including trends in the Issuer’s market(s) or political/regulatory trends.

*Not applicable.*

**Certificate Of Compliance**

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated, December 1, 2020.

Richard Goldstein   
Name of Director or Senior Officer

*“Richard Goldstein”*   
Signature

Chief Financial Officer

Official Capacity

|  |  |  |
| --- | --- | --- |
| ***Issuer Details***  Name of Issuer Canntab Therapeutics Limited. | For Month End  November 30, 2020 | Date of Report  YY/MM/DD  20/12/● |
| Issuer Address:  1 Adelaide Street East, Suite 801 | | |
| City/Province/Postal Code  Toronto, ON M5C 2V9 | Issuer Fax No.  ( ) | Issuer Telephone No.  416-957-6303 |
| Contact Name  Richard Goldstein | Contact Position  CFO | Contact Telephone No.  416-957-6303 |
| Contact Email Address  richard@canntab.ca | Web Site Address  www.canntab.ca | |